Back to Search Start Over

Prostate and pancreas involvement are linked in IgG4-related disease.

Authors :
Liu, Hang
Wallace, Zachary S.
Harvey, Liam
Crotty, Rory
Wu, Chin-Lee
Deshpande, Vikram
O'Shea, Aileen
Harisinghani, Mukesh
Ghebremichael, Musie
Nehra, Ajay
Stone, John H.
Perugino, Cory A.
Source :
Seminars in Arthritis & Rheumatism; Dec2020, Vol. 50 Issue 6, p1245-1251, 7p
Publication Year :
2020

Abstract

Prostate involvement by IgG4-related disease (IgG4-RD) is a rarely described organ manifestation and knowledge regarding its frequency and clinical features is limited. From a single-center cohort, 168 male patients were examined who satisfied the 2019 ACR/EULAR classification criteria or 2012 consensus histopathologic criteria for IgG4-RD. Prostate involvement were identified in 25 (15%) of these cases. The majority of patients with IgG4-RD involving the prostate gland (80%) were symptomatic at presentation with incomplete voiding (64%), urinary frequency (52%), and urinary hesitancy (48%) being the most common complaints. The radiologic presentation of prostate disease is most often a focal abnormality suggesting inflammation rather than a mass lesion. While most patients with IgG4-related prostate disease (89%) experienced recurrence after or during glucocorticoid tapering, patients treated with B cell targeted therapy in this series experienced clinical improvement and were tapered off of glucocorticoids. Additionally, patients with IgG4-RD involving the pancreas (p = < 0.001) were more likely to have prostate involvement than were those with other types of organ involvement. This report provides the first comprehensive clinical description of IgG4-RD involving the prostate gland and links this manifestation with pancreatic involvement. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00490172
Volume :
50
Issue :
6
Database :
Supplemental Index
Journal :
Seminars in Arthritis & Rheumatism
Publication Type :
Academic Journal
Accession number :
147483515
Full Text :
https://doi.org/10.1016/j.semarthrit.2020.09.002